secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2026-05-12T12:05:36+00:00
Accession:  0001493152-26-022401
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon reports Q1 net loss $4.3M; Phase 2 ovarian data shows 14.7-month OS improvement
--------------------------------------------------------------------------------

- Net loss of $4.3M ($0.84 per share) vs $4.1M ($3.15 per share) in Q1 2025; cash $4.8M at March 31, 2026.
- Phase 2 OVATION 2 final data: median OS 45.1 vs 30.4 months (+14.7 months) for IMNN-001+SoC vs SoC alone.
- With PARP inhibitor maintenance, median OS 65.6 vs 41.4 months (+24.2 months) for IMNN-001 arm.
- Phase 3 OVATION 3 enrollment expected to complete by Q1 2029; FDA aligned on BLA path.
- Strategic reorganization in Feb 2026 reduced operating expenses; R&D expenses up to $2.3M from $2.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315226022401/0001493152-26-022401-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315226022401/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-022401

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer